The growing use of copay accumulators — a new weapon against widely used but controversial copay assistance cards that drug makers distribute to consumers — is causing average net prices for medicines to fall, according to a new analysis.
In the first quarter of 2018, net prices after concessions made by drug makers declined 5.6 percent, compared with a 1.7 percent drop in the corresponding quarter a year ago. This occurred even though increases in average wholesale — or list — prices more or less held steady at 6.2 percent versus 6.8 percent in the first quarter of 2017, according to Sector & Sovereign Research, which tracks the pharmaceutical industry.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
